The 20 Best Immune Thrombocytopenic Purpura (ITP) Doctors Near Me in Towson, MD

Muzamil Jawed is a primary care provider, practicing in Internal Medicine in Towson, Maryland. Dr. Jawed is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His clinical expertise encompasses Hypothermia, Adult Immune Thrombocytopenia, Hypothyroidism, and Severe Acute Respiratory Syndrome (SARS). Dr. Jawed is currently accepting new patients.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lutherville, Maryland. She has been practicing medicine for over 17 years. Dr. Kalra is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Kalra is board certified in American Board Of Internal Medicine.

William Houck is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Houck is board certified in American Board Of Internal Medicine.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, and Congenital Hemolytic Anemia. Dr. Naik is board certified in American Board Of Internal Medicine.

Syed Nasir is an Oncologist practicing medicine in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 85 other conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast. Dr. Nasir is currently accepting new patients.

Gang Chen is a Hematologist practicing medicine in Towson, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Colorectal Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.

Mei Tang is a Hematologist practicing medicine in Towson, Maryland. Dr. Tang is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 43 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma.

Dr. Odeniyide is an Assistant Professor in the Division of Pediatric Oncology. Her research focuses on RAS-directed therapies for pediatric rhabdomyosarcoma and her clinical expertise is in the treatment of pediatric solid tumors. Dr. Odeniyide received her undergraduate degree from the University of North Carolina at Chapel Hill and earned her MD from Indiana University School of Medicine. She did her general pediatric residency at the University of North Carolina at Chapel Hill and completed her pediatric hematology/oncology fellowship at Johns Hopkins/ NIH Pediatric Oncology Branch Pediatric Hematology/Oncology joint fellowship training program in 2017. She completed her Ph.D. in cellular and molecular medicine at Johns Hopkins School of Medicine in 2022. Dr. Odeniyide aims to develop and implement novel molecularly targeted therapeutics to treat pediatric cancers with genetic alterations. Her research is focused on the application of small molecule therapeutics for tumors with RAS mutations, a common mutation in cancer for which few effective targeted therapies exist. Her goal is that her research will bring more effective therapeutic options for pediatric sarcoma patients. Dr. Odeniyide is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, and Immune Thrombocytopenic Purpura (ITP). Dr. Odeniyide is board certified in American Board Of Pediatrics.

"In her first decade as a pediatric oncologist, Dr. Symons already has shown an impressive ability to juggle multiple research projects, in addition to caring for patients. One of Dr. Symons' research pursuits focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. The basis of her work stems from the theory that cancer patients' immune systems should recognize tumor cells as foreign and destroy them. This doesn't happen, theorizes Dr. Symons, because the immune system attacks only those cells it perceives as dangerous—not cancer cells, which it sees simply as foreign. That's where her research comes into play. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will ""awaken"" patients' immune systems to the danger of existing cancer cells and, in turn, elicit an immune response. In a separate yet equally compelling research endeavor, Dr. Symons is working to increase the availability of donors for children whose cancer requires bone marrow transplants (BMTs) as a potentially lifesaving treatment. ""It can be challenging to find a 'matched' donor,"" says Dr. Symons, who explains that only about 40 percent of patients who require a BMT find a matched donor. ""Sometimes, we don't have the benefit of time, because remissions can be short-lived. But almost all patients have a half-matched donor: a parent, sibling, or child,"" adds Dr. Symons, who is examining ways to reduce BMT-related complications ordinarily associated with half-matched donors after ablative (high dose) chemotherapy. ""Like anything else that's new, it will take some time to prove that this is a feasible option that's safe,"" she says. But she's optimistic. ""It has the potential to revolutionize BMT."" Dr. Symons knows it's worth the wait. ""Seeing the research I do in the lab translate into clinical trials, then seeing patients in these trials survive long term, is incredibly rewarding,"" she says.". Dr. Symons is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, Leukemia, and Bone Marrow Transplant. Dr. Symons is board certified in American Board Of Pediatrics.

Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG). Dr. Raabe is board certified in American Board Of Pediatrics.

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy. Dr. Pratilas is board certified in American Board Of Pediatrics.

Kristen Schratz is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Baltimore, Maryland. Dr. Schratz is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her clinical expertise encompasses Leukemia, Aplastic Anemia, and Immune Thrombocytopenic Purpura (ITP). Dr. Schratz is board certified in American Board Of Pediatrics.

Dr. Lydia H. Pecker is a pediatric hematologist and Director of the Young Adult Clinic at the Sickle Cell Center for Adults at Johns Hopkins. Dr. Pecker received her undergraduate degree in Africana studies from Brown University and earned her M.D. at the University of Pennsylvania School of Medicine. She completed residency training at Children’s Hospital at Montefiore and completed a fellowship at Children’s National Medical Center and the National Institutes of Health’s National Heart, Lung and Blood Institute before joining the Hopkins faculty in 2016. Dr. Pecker's NIH and foundation-funded research focuses on reproductive health in people with ovaries and sickle cell disease. Dr. Pecker is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Tubal Ligation, and Bone Marrow Transplant. Dr. Pecker is board certified in American Board Of Pediatrics.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant. Dr. Swinnen is board certified in American Board Of Internal Medicine.

Dr. Resar's studies molecular mechanisms leading to cancer, blood diseases, sickle cell anemia, hemophilia and other coagulopathies. Her research focuses on the HMG-I/Y gene family, which is widely overexpressed and functions as oncogenes in human cancers. Her laboratory recently developed transgenic mice overexpressing HMG-I; all mice develop aggressive lymphoid malignancy similar to leukemia and lymphoma in humans. Her studies also demonstrate that this gene is overexpressed in human lymphoid and other malignancies. Translational studies are underway to determine if overexpression of HMG-I is a marker for more aggressive human cancers. Resar's long-term goal is to develop more rational therapies that interfere with HMG-I/Y function in neoplastic transformation. Dr. Resar is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her clinical expertise encompasses Anemia, Sickle Cell Disease, and Immune Thrombocytopenic Purpura (ITP). Dr. Resar is board certified in American Board Of Pediatrics.

Dr. Matthew Merguerian is a pediatric hematologist specializing in bleeding and clotting disorders. His research is focused on bleeding disorders resulting from platelet dysfunction. His lab is interested in understanding the mechanisms behind platelet dysfunction and in developing platelet-targeted therapies that could alleviate abnormal bleeding or clotting. Dr. Merguerian is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His clinical expertise encompasses Blood Clots, Leukemia, and Immune Thrombocytopenic Purpura (ITP). Dr. Merguerian is board certified in American Board Of Pediatrics.

Dr. Friedman is the King Fahd Professor of Oncology and Professor of Pediatrics at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. He received his M.D. from the Harvard Medical School (1983), did his pediatric internship and residency at Boston Children's Hospital (1983-86), and completed a fellowship in pediatric hematology-oncology at Johns Hopkins (1986-89). As a fellow, he did post-doctoral research at the Carnegie Institution Department of Embryology located on the Johns Hopkins Homewood campus. Dr. Friedman has served on the Pediatric Oncology faculty at Johns Hopkins since 1989. His laboratory focuses on investigation of normal and abnormal blood-cell formation. Dr. Friedman also cares for children with cancer, specializing in the treatment of leukemia. Dr. Friedman is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His clinical expertise encompasses Leukemia, Glioma, Acute Lymphoblastic Leukemia (ALL), and Neuroblastoma. Dr. Friedman is board certified in American Board Of Pediatrics.

Dr. Stacy Cooper is the Director of the Pediatric Hematologic Malignancy Program, Director of the Pediatric Hematology/Oncology Fellowship Program, and Clinical Director of the Pediatric Oncology Inpatient Program at the Johns Hopkins School of Medicine. Dr. Cooper received her undergraduate degree in Biology and Spanish at the University of Notre Dame. She earned her M.D. at SUNY Upstate Medical University. She completed her general pediatric residency and chief residency at the Johns Hopkins School of Medicine. She completed her pediatric hematology-oncology fellowship with the Johns Hopkins-National Institutes of Health. Dr. Cooper joined the Johns Hopkins faculty in 2015. Her research focuses on clinical research in acute lymphoblastic leukemia, as well as medical education scholarship related to fellowship training. Dr. Cooper is a member of the American Board of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology Oncology and the Association of Pediatric Program Directors. Dr. Cooper is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Leukemia. Dr. Cooper is board certified in American Board Of Pediatrics.

Emily Rao is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Rao is rated as undefined provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her clinical expertise encompasses Sickle Cell Disease, Von Willebrand Disease (VWD), and Immune Thrombocytopenic Purpura (ITP). Dr. Rao is board certified in American Board Of Pediatrics.